Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adriblastin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| VAD Clorambucil Rituximab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Adriblastin | DRUG | - |
| dexamethasone | DRUG | - |
| Chlorambucil | DRUG | - |
| rituximab | DRUG | - |
| cyclophosphamide | DRUG | - |
| alkeran | DRUG | - |
| Total body irradiation (8Gy/4fr) | PROCEDURE | - |
| vincristine | DRUG | 0,4 mg/day day 1 to day 4 |
Inclusion Criteria: * Mantel cell lymphoma * CD 20+ * At diagnosis or without anterior chemotherapy * Age \>18 and \< 66 years * Ann Arbor ii, III or IV * ECOG \<3 * contraindication for rituximab treatment * Informed consent signed * No cancer anteriory * Renal and hepatic function compatible with...
Adriblastin is a small molecule being studied for the treatment of Mantle Cell Lymphoma, a type of blood cancer. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being evaluated in patients under 65 years of age at diagnosis.
Adriblastin is a small molecule oncology drug. Its specific molecular target has not been disclosed in the available information. The drug is being investigated for its potential role in treating Mantle Cell Lymphoma, but the exact mechanism of action is not specified.
Adriblastin is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The company is conducting clinical research to evaluate the drug's safety and efficacy in Mantle Cell Lymphoma.
Adriblastin is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for the treatment of Mantle Cell Lymphoma, with one completed Phase 2 trial involving 39 patients.
Adriblastin has been studied in one clinical trial with the identifier NCT00285389. This Phase 2 trial, titled 'Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years,' was completed in France. The study enrolled 39 participants aged 18 years and older, with no healthy volunteers.
Adriblastin is a brand name for doxorubicin, an anthracycline antibiotic used in cancer therapy. The drug is being investigated for Mantle Cell Lymphoma under the name Adriblastin. It is a small molecule that works by interfering with DNA replication in cancer cells.